Day: November 21, 2020

5 min read

Opinions expressed by Entrepreneur contributors are their own.

“If I was down to my last dollar, I would spend it on public relations.” —Bill Gates

Every year, millions of startups are launched across the world, each with its own unique selling point, each with a new solution. We hear about some of them, but some we never find out about. These startups use all the latest , understand the basic business principles and spend months, if not years, perfecting their services or product.

Many of these businesses show early-stage promise. They have customers, their technology works or their service is being bought. Where they lack or get stuck is scaling that initial success and interest from their . Translating that potential into a successful and established business is where most entrepreneurs struggle.

This is where PR comes into play, and

How do businesses do more, earn more, and operate better when they have fewer resources and when challenges loom everywhere? It’s a perennial predicament with elusive solutions — and one with which chief marketing officers (CMOs) are certainly familiar. But now, doing more with less has become an urgent mandate rather than a puzzle to ponder, as businesses around the world work to recover from the effects of the COVID-19 pandemic.

Long before the novel coronavirus paralyzed businesses globally, the CMO role was evolving in scope, focus, and sometimes name. New titles such as chief growth officer and chief customer officer emerged to reflect the redefined, more transformational role of today’s marketing and commerce leaders. CMOs were already becoming key players in helping drive customer demand and generate growth. Now, in a world upended by the pandemic, these expectations are amplified.

But if one thinks of challenges as opportunities in

The drugmaker plans to distribute 1 billion doses over the next year.

Grow Your Business, Not Your Inbox

Stay informed and join our daily newsletter now!

3 min read

This article was translated from our Spanish edition using AI technologies. Errors may exist due to this process.

  • According to Joaquín Duato, vice president of the Executive Committee of Johnson & Johnson, its coronavirus vaccine will be released in the second half of 2021.
  • The drugmaker plans to distribute 1 billion doses at a cost of less than $ 10.

The race to obtain the long-awaited vaccine against COVID-19 is increasingly close. Pharmaceutical Janssen, part of the Johnson & Johnson group, promises that its vaccine will be available by the second half of 2021. And the best thing is the price, since it would cost less than 10 dollars, that is, about 200 Mexican pesos.

Joaquín Duato, vice

The ongoing rally has not just benefited a few, but almost all companies — at least in the Nifty50 universe.

According to Bloomberg data, about 86 per cent of the components are currently trading above their 200-day moving average (DMA) — a key technical indicator to study long-term trend of a stock.

The last time a higher percentage of stocks traded above the 200-DMA was in 2016. The 200-DMA is the average closing price for the past 200 trading sessions. A stock trading above 200-DMA is considered to be in bullish territory.

However, some believe a high reading is a warning sign, as it indicates that the market is over-bullish. The benchmark is currently hovering around its lifetime high.

The index of 50 blue-chip companies has rallied 10.5 per cent this month, and is